import
agent
viral
hepat
worldwid
caus
sever
cours
infect
pregnant
women
immunosuppress
patient
date
hev
infect
treat
ribavirin
rbv
major
drawback
therapi
rbv
approv
administr
pregnant
women
viru
acquir
mutat
render
intrahost
popul
less
sensit
even
resist
rbv
one
propos
mode
action
rbv
direct
mutagen
effect
viral
genom
induc
mismatch
subsequ
nucleotid
substitut
transit
event
drive
alreadi
errorpron
viral
replic
beyond
error
threshold
caus
viral
popul
extinct
contrast
expand
heterogen
viral
popul
facilit
select
mutant
virus
enhanc
replic
fit
emerg
mutant
virus
lead
therapeut
failur
consequ
onset
rbv
treatment
chronic
hevinfect
individu
result
two
diverg
outcom
viral
extinct
versu
select
fitnessenhanc
virus
follow
overview
rna
virus
treat
rbv
clinic
summari
differ
antivir
mode
action
drug
focu
mutagen
effect
rbv
hev
intrahost
popul
hev
abl
overcom
lethal
mutagenesi
genotyp
endem
africa
southeast
asia
mexico
zoonot
genotyp
predominantli
found
northern
america
europ
northern
asia
summar
hepevirida
studi
group
intern
committe
taxonomi
virus
other
infect
hev
usual
selflimit
caus
arthralgia
flulik
myalgia
vomit
symptom
characterist
hepat
like
jaundic
itch
progress
chronic
gener
describ
pregnant
women
immunosuppress
individu
patient
recov
form
solid
organ
transplant
data
hivcoinfect
patient
contradictori
still
discuss
extens
review
debe
et
al
accord
world
health
organ
year
million
individu
newli
infect
hev
three
million
symptomat
case
hev
infect
report
worldwid
year
hevrel
death
hev
must
reconsid
major
global
health
burden
appropri
resourc
redirect
toward
effect
control
eventu
erad
recent
studi
report
extrahepat
manifest
hev
accumul
detail
potenti
connect
hev
infect
neurolog
disord
includ
syndrom
ribavirin
rbv
broadspectrum
antivir
agent
numer
clinic
applic
viral
pathogen
current
treatment
option
chronic
infect
hev
patient
sever
public
document
emerg
singlenucleotid
variant
snv
viral
genom
caus
either
reduc
rbv
sensit
rbv
resist
recent
studi
also
indic
hev
acquir
mutat
rbv
therapi
decreas
sensit
rbv
treatment
regim
vitro
importantli
vivo
articl
start
overview
select
rna
virus
clinic
treat
rbv
summar
drug
differ
antivir
mode
action
second
part
focus
mutagen
effect
rbv
hev
intrahost
popul
hev
abl
overcom
lethal
mutagenesi
induc
guanosin
analog
hepat
e
viru
hev
first
describ
novel
agent
respons
enter
transmit
nona
nonb
hepat
rey
colleagu
year
first
document
epidem
outbreak
retrospect
identifi
hev
infectiontransmit
via
fecalor
routein
new
delhi
india
hev
nonenvelop
singlestrand
rna
viru
kb
genom
posit
orient
three
open
read
frame
orf
encod
nonstructur
protein
compris
methyltransferas
papainlik
cystein
proteas
helicas
rnadepend
rna
polymeras
rdrp
connect
ydomain
hypervari
region
hvr
capsid
protein
small
protein
whose
function
yet
complet
understood
viral
subgenom
rna
compar
mammalian
mrna
flank
methylguanin
cap
poli
tail
hev
recent
taxonom
reassign
genu
orthohepeviru
famili
hepevirida
differ
sequenc
isol
led
current
classif
seven
genotyp
four
infect
human
ie
genotyp
sole
human
pathogen
mainli
transmit
oral
fecescontamin
drink
water
rbv
describ
broadspectrum
antivir
sever
dna
rna
virus
sinc
numer
studi
report
vitro
antivir
properti
rbv
figur
provid
overview
select
rna
virus
rbv
shown
activ
hepat
c
viru
hcv
flavivirida
dengu
viru
denv
flavivirida
respiratori
syncyti
viru
rsv
paramyxovirida
influenza
b
viru
orthomyxovirida
chikungunya
viru
chikv
togavirida
polioviru
picornavirida
hantaan
viru
bunyavirida
lassa
viru
arenavirida
figur
read
would
like
refer
review
like
studi
multipl
virus
famili
flavivirida
cranc
et
al
investig
vitro
antivir
properti
rbv
flavivirus
includ
denv
japanes
enceph
viru
jev
yellow
fever
viru
yfv
inhibit
viru
replic
observ
test
flavivirus
furthermor
effect
rbv
could
confirm
vivo
yfv
use
hamster
model
administ
earli
upon
infect
howev
effect
could
confirm
nonhuman
primat
model
therefor
studi
requir
evalu
possibl
applic
rbv
treatment
option
yfv
dosag
well
time
point
treatment
repres
major
hurdl
need
overcom
addit
hemorrhag
fevercaus
virus
categor
famili
arena
bunya
togavirida
demonstr
suscept
inhibit
rbv
figur
exampl
lassa
viru
antivir
effici
rbv
proven
vitro
vivo
guinea
pig
monkey
hantavirus
ie
hantaan
viru
phlebovirus
ie
rift
valley
fever
viru
rvf
also
shown
suscept
rbv
treatment
mous
model
hantaan
viru
increas
surviv
milder
sign
diseas
describ
experiment
rvf
infect
mice
hamster
rbv
led
prevent
death
delay
death
onset
milder
symptom
depend
time
point
administr
gener
higher
dose
rbv
need
inhibit
flavivirus
compar
arena
bunya
hantavirus
chikv
rbv
also
demonstr
antivir
effect
although
lesser
extent
compar
nevertheless
synergist
effect
rbv
could
demonstr
vitro
moreov
antivir
properti
rbv
could
shown
member
picornavirida
footandmouth
diseas
viru
fmdv
polioviru
pv
inhibit
rbv
figur
demonstr
antivir
effect
although
lesser
extent
compar
nevertheless
synergist
effect
rbv
could
demonstr
vitro
moreov
antivir
properti
rbv
could
shown
member
picornavirida
footandmouth
diseas
viru
fmdv
polioviru
pv
inhibit
rbv
figur
figur
antivir
properti
ribavirin
rbv
rna
virus
broadspectrum
antivir
properti
rbv
report
sever
rna
virus
depict
select
differ
viral
famili
respect
genu
speci
virus
rbv
clinic
approv
highlight
orang
box
virus
lethal
mutagenesi
increas
mutat
rate
propos
possibl
rbv
mechan
indic
blue
display
broad
antivir
activ
wide
rang
rna
virus
clinic
data
applic
rbv
still
limit
restrict
virus
initi
rbv
consid
treatment
option
influenza
b
viru
infect
howev
clinic
trial
show
inconclus
data
although
studi
report
improv
symptom
influenza
viru
infect
result
gener
inconsist
due
lack
conclus
data
clinic
trial
coupl
develop
altern
antivir
therapi
rbv
never
approv
treatment
influenza
viru
nonetheless
lassa
viru
hcv
rsv
promin
exampl
virus
rbv
receiv
approv
antivir
compound
clinic
applic
rbv
shown
effect
treat
patient
suffer
lassa
fever
administ
oral
intraven
preor
postexposur
prophylaxi
rbv
approv
food
drug
administr
fda
treatment
option
hcv
combin
pegyl
standard
treatment
chronic
hcv
infect
two
decad
shown
failur
monotherapi
alon
combin
therapi
rbv
effect
subsequ
repetit
monotherapi
howev
sustain
virolog
respons
svr
rate
vari
among
genotyp
dual
therapi
associ
sever
side
effect
nowaday
rbv
longer
standardofcar
antihcv
therapi
replac
directact
antivir
daa
initi
trial
treatment
rsv
infect
show
reduc
durat
hospit
requir
mechan
ventil
routin
use
rbv
rsvinfect
children
recommend
howev
treatment
consid
individu
case
display
broad
antivir
activ
wide
rang
rna
virus
clinic
data
applic
rbv
still
limit
restrict
virus
initi
rbv
consid
treatment
option
influenza
b
viru
infect
howev
clinic
trial
show
inconclus
data
although
studi
report
improv
symptom
influenza
viru
infect
result
gener
inconsist
due
lack
conclus
data
clinic
trial
coupl
develop
altern
antivir
therapi
rbv
never
approv
treatment
influenza
viru
nonetheless
lassa
viru
hcv
rsv
promin
exampl
virus
rbv
receiv
approv
antivir
compound
clinic
applic
rbv
shown
effect
treat
patient
suffer
lassa
fever
administ
oral
intraven
preor
postexposur
prophylaxi
rbv
approv
food
drug
administr
fda
treatment
option
hcv
combin
pegyl
standard
treatment
chronic
hcv
infect
two
decad
shown
failur
monotherapi
alon
combin
therapi
rbv
effect
subsequ
repetit
monotherapi
howev
sustain
virolog
respons
svr
rate
vari
among
genotyp
dual
therapi
associ
sever
side
effect
nowaday
rbv
longer
standardofcar
antihcv
therapi
replac
directact
antivir
daa
initi
trial
treatment
rsv
infect
show
reduc
durat
hospit
requir
mechan
ventil
routin
use
rbv
rsvinfect
children
recommend
howev
treatment
consid
individu
case
taken
togeth
sinc
first
descript
antivir
rbv
shown
activ
broad
rang
rna
virus
howev
due
limit
clinic
trial
data
support
vivo
efficaci
clinic
applic
current
limit
minor
virus
broad
antivir
effect
rbv
numer
rna
virus
suggest
differ
mode
action
molecul
inde
sever
antivir
mechan
describ
past
summar
figur
among
indirect
mechan
tcellmedi
effect
describ
hcv
figur
balanc
helper
cell
chang
switch
helper
type
phenotyp
helper
type
studi
hultgren
et
al
inhibit
vitro
tcell
prolifer
well
chang
secret
cytokin
observ
simultan
alanin
transaminas
alt
level
serum
reduc
chang
hcv
titer
furthermor
earli
switch
helper
type
immun
respons
helper
type
immun
respons
associ
diseas
progress
develop
chronic
thu
rbv
restor
helper
phenotyp
need
balanc
express
secret
cytokin
produc
type
helper
cell
anoth
exampl
immunomodulatori
effect
describ
rbv
rsv
infect
propos
helper
type
cytokin
respons
initi
cascad
lead
airway
hyperreact
turn
block
rbv
treatment
figur
anoth
indirect
mode
action
rbv
inhibit
cellular
inosin
monophosph
dehydrogenas
impdh
alreadi
propos
figur
uptak
cell
rbv
phosphoryl
rbv
mono
di
triphosph
rmp
rdp
rtp
respect
rmp
repres
good
mimic
inosin
monophosph
imp
therebi
inhibit
synthesi
imp
xanthosin
monophosph
xmp
impdh
consequ
guanosin
monophosph
gmp
subsequ
guanosin
triphosph
gtp
synthes
vitro
replic
measl
viru
vero
cell
could
block
addit
xmp
gmp
lesser
extent
also
imp
underlin
mode
action
rmp
linear
correl
deplet
gtp
pool
vitro
antivir
activ
rbv
human
parainfluenza
viru
yfv
confirm
furthermor
addit
guanosin
cell
cultur
restor
antivir
activ
rbv
gb
viru
b
gbvb
contrast
vitro
experi
lassa
viru
hantaan
viru
indic
rbv
primarili
act
via
deplet
gtp
pool
two
virus
moreov
experi
influenza
viru
show
linear
correl
intracellular
gtp
pool
viral
replic
increas
concentr
rbv
addit
author
observ
complet
restor
influenza
viru
replic
addit
guanosin
effect
guanosin
gmp
antivir
effect
rbv
influenza
viru
mice
could
demonstr
overal
data
suggest
mechan
mode
action
rbv
exist
influenc
rbv
express
ifnstimul
gene
isg
controversi
literatur
studi
vivo
vitro
come
hcv
rsv
field
rbv
abl
increas
antivir
effect
ifnbas
therapi
restor
ifnrespons
hcvinfect
liver
also
direct
ifnindepend
upregul
isg
propos
howev
recent
studi
hcv
patient
receiv
rbv
monotherapi
show
downregul
abnorm
preactiv
isg
chromatin
remodel
modul
histon
methyl
result
higher
liver
suscept
ifn
lower
baselin
express
certain
isg
rna
virus
well
cellular
mrna
harbor
cap
structur
end
rbvinduc
reduct
gtp
pool
within
cell
propos
also
effect
cap
effici
rna
virus
figur
exampl
denv
encod
omethyltranferas
nterminu
polymeras
term
dv
dv
bind
gtp
catalyz
format
cap
structur
rbv
treatment
less
gtp
present
rtp
shown
compet
bind
dv
therebi
block
synthesi
cap
likewis
rbv
directli
strongli
inhibit
viral
mrna
guanylyltransferas
vaccinia
viru
thu
prevent
cap
nascent
viral
rna
howev
mechan
controversi
discuss
literatur
rna
virus
display
cap
structur
end
therefor
mode
action
account
exclus
observ
effect
rbv
anoth
suggest
mechan
direct
impact
rbv
treatment
function
viral
polymeras
figur
b
rtp
thought
directli
inhibit
viral
rna
replic
recogn
viral
polymeras
therebi
lead
chain
termin
prevent
bind
nucleotid
import
elong
cellfre
system
rtp
shown
inhibit
rna
polymeras
influenza
viru
moreov
inhibit
viral
rna
synthesi
vesicular
stomat
viru
vsv
presenc
rmp
rdp
rtp
describ
triphosphoryl
form
least
activ
would
argu
mode
action
base
incorpor
rtp
nascent
viral
rna
vsv
studi
inhibitori
effect
rdp
la
cross
viru
rna
synthesi
also
report
interestingli
crotti
et
al
could
demonstr
rtp
inde
employ
pv
rdrp
integr
rbv
act
mutagen
anoth
exampl
effect
rtp
viral
polymeras
case
reoviru
rankin
et
al
propos
rtp
bind
close
catalyt
site
transcriptas
therebi
affect
helicas
function
subsequ
lower
bind
affin
viral
rna
consequ
elong
viral
rna
inhibit
interestingli
effect
cap
activ
demonstr
nucleotid
bind
site
polymeras
highli
conserv
among
hcv
genotyp
support
propos
mechan
inde
vitro
analysi
show
minor
decreas
hcv
replic
howev
clinic
trial
rbv
monotherapi
mild
decreas
hcv
replic
notic
recent
year
mutagen
effect
rbv
via
incorpor
newli
synthes
rna
genom
lead
viral
extinct
describ
sever
rna
virus
figur
contrast
dna
virus
major
characterist
rna
virus
occurr
cloud
relat
genet
distinct
variant
infect
patient
often
refer
quasispeci
howev
term
quasispeci
refer
particular
mutationselect
balanc
natur
select
act
group
rather
individu
simpli
surrog
genet
heterogen
quasispeci
behavior
demonstr
experiment
artifici
expand
polioviru
popul
infect
mice
evid
lack
quasispeci
behavior
mani
virus
includ
hev
divers
intrahost
viral
popul
result
lack
proofread
activ
rdrp
howev
due
high
variat
viral
isol
close
error
threshold
would
lead
reduct
viral
fit
incorpor
rbv
newli
synthes
rna
genom
therebi
increas
frequenc
mutat
popul
push
viru
error
threshold
result
viral
extinct
mechan
action
rbv
describ
least
vitro
fmdv
polioviru
hcv
gbvb
hantaan
viru
hev
ever
sinc
first
report
sidwel
et
al
describ
rbv
broadspectrum
antivir
multipl
discuss
mechan
action
cours
one
alway
keep
mind
vitro
data
propos
model
aros
translat
vivo
situat
remark
enough
monotherapi
rbv
potent
effect
lassa
viru
hev
futur
studi
address
question
regard
biocompat
rbv
avail
target
liver
investig
intracellular
concentr
account
differ
propos
mechanismsfor
exampl
outcompet
cellular
nucleosid
triphosph
ntp
misincorpor
summari
sever
mechan
postul
rbv
activ
among
indirect
immunomodulatori
mechan
effect
impdh
furthermor
mechan
viru
describ
inhibit
cap
effici
viral
polymeras
mutagen
effect
newli
synthes
rna
genom
rna
virus
exist
clonal
popul
genom
within
infect
host
rather
diversifi
swarm
relat
nonident
genom
sequenc
heterogen
viral
populationalso
refer
mutant
cloud
mutant
swarm
mutant
spectrai
capabl
better
adapt
chang
environment
condit
rapidli
evolv
passag
host
host
due
high
heterogen
concept
quasispeci
mainli
develop
manfr
eigen
peter
schuster
demonstr
viral
heterogen
fmdv
vsv
domingo
colleagu
holland
colleagu
first
extrapol
concept
virolog
viral
popul
product
high
replic
rate
found
rna
virus
coupl
lack
rdrp
proofread
function
hcv
estim
new
virion
produc
one
infect
individu
per
day
estim
hev
current
exist
although
compar
high
replic
rate
assum
data
end
repair
mechan
identifi
small
rna
viral
polymeras
coronavirus
exampl
exoribonucleas
exon
domain
within
nonstructur
protein
identifi
essenti
highfidel
replic
hcv
pyrophosphorolyt
ntpmediat
nucleotid
excis
activ
rdrp
describ
viral
mechan
remov
misincorpor
base
despit
report
rna
virus
like
also
hev
real
proofread
capabl
caus
errorpron
replic
viral
genom
togeth
short
gener
time
result
highli
divers
intrahost
popul
expect
hev
also
exist
heterogen
popul
within
infect
individu
earli
public
reli
classic
tool
detect
diversif
viral
genom
includ
restrict
fragment
length
polymorph
rflp
haplotyp
profil
clonal
sequenc
character
hev
intrahost
divers
recent
nextgener
sequenc
ng
method
util
studi
distribut
snv
hev
genom
time
hev
rna
viru
popul
exist
close
proxim
socal
genom
error
threshold
defin
maximum
error
rate
still
guarante
mainten
transmiss
genet
inform
master
sequenc
replic
importantli
mutat
rate
beyond
extinct
threshold
caus
sharp
reduct
effici
transmiss
genet
inform
contain
popul
master
sequenc
next
gener
viral
progeni
phenomenon
sometim
refer
error
catastroph
major
genom
popul
nonfunct
broadspectrum
antivir
agent
like
rbv
caus
increas
mutat
rate
potenti
result
extinct
viru
popul
process
call
lethal
mutagenesi
howev
mutat
viral
intrahost
popul
acquir
mutat
account
drug
resist
decreas
sensit
rbv
direct
consequ
boost
complex
mutat
spectra
shown
sever
virus
like
hcv
fmdv
pv
sindbi
viru
also
hev
dynam
hev
popul
patient
rbv
therapi
fulli
understood
recent
studi
report
rna
virus
point
dichotomi
oppos
outcom
result
rbv
therapi
rbvinduc
lethal
mutagenesi
result
viral
extinct
versu
accumul
mutat
benefici
viru
popul
lead
therapeut
failur
consequ
emerg
rbvresist
mutat
subsequ
treatment
failur
clinician
could
draw
back
combin
therapi
overcom
avoid
phenomenon
possibl
combin
one
mutagen
convent
antivir
drug
use
sever
rna
mutagen
combin
sequenc
propos
peral
domingo
hev
one
pathogen
virus
current
treat
rbv
offlabel
drug
altern
therapi
evalu
small
patient
cohort
limit
success
consider
side
effect
addit
vitro
data
suggest
care
assess
ifn
treat
hev
consid
high
mortal
rate
pregnant
women
urgent
need
extens
research
field
novel
antihev
treatment
regimen
requir
patient
fail
achiev
sustain
virolog
respons
rbv
therapi
hev
treatment
option
particularli
import
solid
organ
transplant
set
reduct
immunosuppress
beyond
certain
level
lead
reject
allograft
hepat
caus
hev
imped
recent
two
independ
studi
abl
correl
rbv
treatment
failur
emerg
novel
singlenucleotid
variat
viral
genom
treatment
research
group
identifi
variant
previous
describ
well
new
variant
polymeras
region
addit
todt
et
al
also
determin
nine
addit
snv
orf
studi
mutat
emerg
sever
patient
addit
overal
increas
viral
intrahost
heterogen
could
shown
author
demonstr
signific
increas
number
site
exhibit
snv
synonym
well
nonsynonym
viral
popul
first
administr
rbv
nine
patient
phenomenon
observ
orf
hev
genom
interestingli
increas
heterogen
revers
declin
number
snv
site
rbv
treatment
stop
strikingli
none
describ
variant
becam
domin
viral
popul
treatment
result
decreas
sensit
rbv
clone
hev
subgenom
report
replicon
tissu
cultur
mutat
alter
viral
replic
efficaci
increas
replic
rate
rbv
sensit
unmodifi
rbv
treatment
fail
patient
other
abl
clear
viru
rbv
monotherapi
remain
open
question
rbv
shown
block
hev
replic
deplet
cellular
gtp
pool
cell
cultur
model
system
addit
strong
mutagen
effect
rbv
hev
genom
vivo
describ
rbv
inhibit
impdh
thu
caus
twofold
reduct
intracellular
gtp
pool
increas
ctp
utp
concentr
time
hev
genom
replic
cyclic
process
altern
synthesi
negativestrand
rna
positivestrand
rna
replic
process
extrins
administ
rtp
randomli
incorpor
nascent
negativestrand
rna
result
pair
either
pyrimidin
base
cytidin
uracil
figur
upper
panel
negativestrand
antigenom
rna
serv
templat
subsequ
product
positivestrand
genom
rna
rdrp
subsequ
incorpor
randomli
cytidin
uracil
rbv
residu
locat
antigenom
templat
figur
middl
panel
stochast
incorpor
lead
nucleotid
substitut
newli
synthes
viral
genom
addit
rbv
also
incorpor
positivestrand
rna
genom
lead
increas
amount
replicationdefect
viral
genom
packag
capsid
ultim
lead
increas
frequenc
replicationdefect
virion
addit
new
antigenom
templat
produc
defect
positivestrand
genom
misincorpor
amplifi
replic
process
figur
lower
panel
result
fixat
transit
substitut
nascent
rna
transit
purinetopurin
g
pyrimidinetopyrimidin
c
nucleotid
substitut
preferenti
enrich
rbv
monotherapi
lead
observ
synonym
exchang
well
amino
acid
replac
favor
surviv
viral
popul
whether
rbv
also
inhibit
hev
methyltransferas
compar
direct
inhibit
vaccinia
viru
guanylyltransferas
see
rtp
incorpor
cap
analog
thu
impact
correct
translat
investig
yet
mutagen
effect
rbvbase
therapi
diverg
effect
hev
popul
may
impact
therapi
success
one
hand
rbv
increas
mutat
rate
viral
genom
drive
popul
toward
extinct
threshold
contrast
increas
variabl
viral
popul
result
select
variant
improv
replic
fit
becom
domin
viral
popul
associ
therapeut
failur
advantag
variant
could
downregul
replic
machineri
thu
prevent
accumul
mutat
shown
vitro
data
revers
engin
variant
hev
cell
cultur
system
ii
increas
viral
polymeras
fidel
hypothes
debe
et
al
varianta
mutant
substitut
rdrpwhich
could
hinder
incorpor
rbv
viral
genom
fact
lab
esteban
domingo
abl
dissect
multistep
process
viral
adapt
mutagen
nucleosid
analog
fmdv
led
extinct
escap
chang
fidel
polymeras
hev
lifethreaten
infect
immunosuppress
individu
fail
achiev
svr
rbv
treatment
current
clinician
altern
therapi
regimen
avail
recent
studi
suggest
heterogen
viral
popul
abl
acquir
snv
decreas
rbv
sensit
data
support
conclus
whereupon
mutagen
effect
broadspectrum
antivir
agent
lead
increas
heterogen
intrahost
viral
popul
introduc
race
viru
tri
gain
accumul
benefici
variat
mutagen
potenti
rbv
intend
drive
viru
beyond
error
threshold
thu
lethal
mutagenesi
result
viral
extinct
